Skip to content

Jazz Pharmaceuticals

US · JAZZ #1123 by market cap Listed 1970
230.26 -6.19 -2.62%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Founded
2005
CEO
Ms. Renee D. Gala
Employees
2,890
Headquarters
Dublin, Dublin, Ireland
Fiscal year end
12-31
Website
jazzpharma.com

Company profile

Exchange
US
Symbol
JAZZ
Market-cap rank
#1123
Listing date
1970-01-01
Market cap
14.78B
Float cap
14.33B
Shares out
64.19M
Float shares
62.25M

Sectors & themes

Biotechnology Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.

Jazz Pharmaceuticals discussion 0 comments

Add a comment